OBI Pharma, Inc. to Present its Flagship Immunotherapy at Annual European Society for Medical Oncology Meeting
OBI Pharma, Inc., a Taiwan biotech developing therapeutic agents and next-gen active immunotherapies for a range of unmet medical needs and indications, is scheduled to host an industry-sponsored satellite symposium at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting taking place in Copenhagen, Denmark, next month. The symposium, titled "Novel Approaches to Active Immunotherapy in Oncology – Targeting Globo Series with Adagloxad Simolenin," will review data on targeting Globo Series antigens in metastatic breast cancer and other cancers with OBI Pharma’s investigational active immunotherapy, Adagloxad Simolenin (formerly OBI-822), and will examine the future of active immunotherapy in oncology.…